Advertisement

Topics

NICE recommends lenvatinib for differentiated thyroid cancer

09:32 EST 15 Feb 2018 | ecancermedicalscience

The National Institute for Health and Care Excellence (NICE) has issued its final appraisal decision (FAD) recommending reimbursement of lenvatinib for the treatment of progressive, locally advanced or metastatic, differentiated...

Original Article: NICE recommends lenvatinib for differentiated thyroid cancer

NEXT ARTICLE

More From BioPortfolio on "NICE recommends lenvatinib for differentiated thyroid cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...